London stock exchange
Stocks and Finance

AstraZeneca

AstraZeneca 11/05/2012

07:36 : AstraZeneca Buys Back 316,716 Shares At 2682P/Share - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) Friday said it purchased, for cancellation, 316,716 ordinary shares at a price of 2682 pence per share on May 10. Shares at 0707 GMT down 6 pence, or 0.2%, at 2671 pence. By Tapan Panchal, ...

AstraZeneca 08/05/2012

08:01 : AstraZeneca Buys Back 311,479 Shares/2730P - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) said Tuesday that it purchased for cancellation 311,479 of its ordinary shares at 2730 pence per share on May 4. Shares at 0740 GMT down 7 pence, or 0.26%, at 2704 pence valuing the company ...

AstraZeneca 05/05/2012

23:35 : Business agenda: bookmaker's board faces big hurdle - On the news list this week: William Hill's potentially stormy annual meeting; British Airways and Sainsbury's results; and Fred Goodwin's lingering legacyRevolution is in vogue, as you may have read elsewhere. Boards from Barclays ...
Source : guardian-co-uk

AstraZeneca 04/05/2012

07:30 : AstraZeneca Buys Back 311,816 Shares/2727P - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) said Friday that it purchased for cancellation 311,816 of its ordinary shares at 2727 pence per share on May 3. Shares closed Thursday at 2727.5 pence valuing the company at GBP34.62 billion. ...

AstraZeneca 29/04/2012

14:17 : AstraZeneca CEO Brennan To Retire With GBP40 Million Pay-Newspaper - LONDON -(Dow Jones)- David Brennan, the departing CEO of AstraZeneca PLC (AZN.LN), will retire with a pension worth almost GBP1 million per year, as part of a broader "golden goodbye" package worth up to GBP40 million, the Sunday Times ...

AstraZeneca 27/04/2012

09:26 : AstraZeneca Buys Back 316,066 Shares At 2,686P - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) said Friday that it bought for cancellation 316,066 shares at 2,686 pence per share. -Shares at 0906 GMT, down 13 pence, or 0.51%, at 2,653 pence valuing the company at GBP33.88 million. ...

AstraZeneca 26/04/2012

23:40 : AstraZeneca chief quits as profits slump by 40 per cent - The chief executive of AstraZeneca, David Brennan, shocked the markets by announcing his resignation yesterday in an apparent boardroom coup just hours before the pharmaceuticals giant's shareholder meeting kicked off.
23:24 : David Brennan steps down as AstraZeneca profits tumble - David Brennan's resignation after six years at the helm of AstraZeneca, alongside a 38pc drop in first-quarter profits, sent shares the pharmaceutical giant tumbling 6pc.
Source : telegraph-co-uk
20:48 : AstraZeneca shareholders see £2.2bn wiped off value after chief David ... - AstraZeneca shareholders saw more than £2.2bn wiped off the pharmaceutical group's value as a boardroom shake-up following a period of investor unrest led to the abrupt departure of chief David Brennan.
Source : telegraph-co-uk
17:07 : Earnings drive FTSE 100 higher for third day - Britain's top shares pushed higher on Thursday, notching up a third session of gains as investors digested a big bag of blue chip results, with advances in oil majors outweighing a heavy fall in drugs firm AstraZeneca.
Source : ibtimes-co-uk
13:52 : AstraZeneca CEO quits as drug sales tumble - LONDON (Reuters) - AstraZeneca's chief executive David Brennan is to step down on June 1 in an abrupt exit after six years in the top job, following rising investor discontent at the company's performance.
Source : reuters-com
13:20 : AstraZeneca chief to step down - AstraZeneca chief executive David Brennan is to step down on June 1st in an abrupt exit after six years in the top job, following rising investor discontent at the company's performance.
Source : irishtimes-com
12:55 : David Brennan's successor faces unenviable task at AstraZeneca - Brennan and the new stand-in chief, finance director Simon Lowth, repeatedly said today that AstraZeneca has a clear strategy – but is the strategy fit for the next five years'David Brennan says it was "entirely my decision" to retire ...
Source : guardian-co-uk
12:54 : AstraZeneca: What the analysts say - Expert reaction has been mixed – and not entirely negative – following the news of David Brennan's resignationDavid Brennan quit abruptly as chief executive of AstraZeneca on Thursday, just hours before the drugmaker's annual meeting. ...
Source : guardian-co-uk
11:28 : AstraZeneca boss David Brennan quits in boardroom coup - Brennan, who said he had been contemplating his departure for some time, will be temporarily replaced by finance director Simon Lowth from 1 JuneAstraZeneca's chief executive David Brennan quit abruptly on Thursday after more than six years in the post, ...
Source : guardian-co-uk
09:59 : Profile: David Brennan - David Brennan announced this morning that he was to step down after six years in charge of pharmaceutical giant AstraZeneca, just as it posted a 38pc drop in first-quarter profits. We take a look at his career to date.
Source : telegraph-co-uk
08:44 : Boardroom 'coup' at AstraZeneca - The chief executive and chairman of AstraZeneca are both retiring early, encouraged by the non-executive directors, amid growing shareholder discontent.
Source : news-bbc-co-uk
08:42 : AstraZeneca CEO quits as profits tumble - David Brennan will be replaced on an interim basis by chief financial officer Simon Lowth while a permanent successor from inside or outside the company is foundAstraZeneca chief executive David Brennan is to step down on 1 June in an abrupt exit that ...
Source : guardian-co-uk

AstraZeneca 23/04/2012

16:18 : AstraZeneca to buy gout drug maker Ardea Biosciences for $1.26bn - AstraZeneca has moved to boost its slim pipeline of new drugs by agreeing a $1.26bn (£783m) deal to buy Californian biotechnology group Ardea Biosciences.
Source : telegraph-co-uk
09:26 : AstraZeneca buys gout drug maker Ardea - Big drugmakers are trying to beef up their portfolios by buying smaller developers with promising new treatmentsAmid a flurry of M&A activity in the biotechnology industry, British drugmaker AstraZeneca has agreed a $1.26bn (£781m) ...
Source : guardian-co-uk
07:14 : AstraZeneca agrees to buys Ardea for $1.26 billion - LONDON (Reuters) - AstraZeneca has agreed to buy U.S. biotech company Ardea Biosciences for $1.26 billion (782 million pounds), giving it access to a new drug for treating gout patients in the latest deal to try and bolster its weak ...
Source : reuters-com

AstraZeneca 18/04/2012

07:38 : AstraZeneca Buys For Cancellation 301,651 Shares At 2,821P - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) said Wednesday that it bought for cancellation 301,651 shares at 2,821 pence per share. -Shares at 0714 GMT, down 6 pence, or 0.2%, at 2,833.5 pence valuing the company at GBP36.12 billion. ...

AstraZeneca 12/04/2012

08:54 : AstraZeneca Buys Back 305,856 Shares/2782P - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) said Thursday that it purchased for cancellation 305,856 of its ordinary shares at 2782 pence per share on April 11. Shares at 0830 GMT down 7 pence, or 0.3%, at 2785.5 pence valuing the ...

AstraZeneca 09/04/2012

17:24 : Some AstraZeneca investors want CEO replaced - FT - LONDON (Reuters) - Some of AstraZeneca's biggest investors are calling for a radical shake-up of the drugmaker's board and executive team, including the replacement of David Brennan as CEO, the Financial Times reported on Monday.
Source : reuters-com
16:58 : Some AstraZeneca Shareholders Seeking Replacement Of CEO Brennan -FT - DOW JONES NEWSWIRES Some shareholders of AstraZeneca PLC (AZN, AZN.LN) are seeking the replacement of Chief Executive David Brennan, the Financial Times reported Monday. The FT said the company's top 20 investors "have become unsually ...

AstraZeneca 05/04/2012

08:52 : AstraZeneca Buys Back 303,195 Shares/2807P - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN) said Thursday it purchased for cancellation 303,195 of its ordinary shares at 2807 pence per share on April 4. Shares at 0835 GMT down 4 pence, or 0.1%, at 2777.5 pence valuing the company ...

AstraZeneca 03/04/2012

08:33 : AstraZeneca Buys 303,743 Own Shares To Cancel - LONDON -(Dow Jones)- AstraZeneca PLC (AZN.LN), a global research-based biopharmaceutical company, said Tuesday it purchased for cancellation 303,743 ordinary shares of AstraZeneca at a price of 2801 pence per share ...

AstraZeneca 02/04/2012

23:06 : AstraZeneca and Amgen to develop respiratory disease drugs - UK drugmaker AstraZeneca and Amgen, the world's largest biotech company, have announced a tie-up to develop and sell treatments for auto-immune and respiratory diseases.
Source : telegraph-co-uk
21:08 : UPDATE: Amgen, AstraZeneca Collaborate On Anti-Inflammatory Drugs - --AstraZeneca, Amgen to co-develop, commercialize 5 drugs targeting inflammatory diseases --AstraZeneca to pay Amgen $50 million up-front, fund majority of costs in initial years --Drugs developed to treat psoriasis, Crohn's disease, colitis

AstraZeneca 01/04/2012

19:18 : The Business Week In Review: AstraZeneca, Bob Dudley, the Financial Service - In profit...AstraZeneca boss David Brennan graced the downstairs bit of this column last week. An error, we now admit: he's done all right for himself.
actualidad AstraZeneca -

Copyright © 2009 Finaperf.com - Bourse - Börse - Day trading - Bolsa - Tous droits réservés
Site édité par Yanga.net - Contacts